ANI Pharmaceuticals (ANIP) – Analysts’ Recent Ratings Updates

ANI Pharmaceuticals (NASDAQ: ANIP) recently received a number of ratings updates from brokerages and research firms:

  • 11/19/2019 – ANI Pharmaceuticals was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 11/12/2019 – ANI Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “
  • 11/7/2019 – ANI Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 11/7/2019 – ANI Pharmaceuticals had its price target lowered by analysts at Raymond James from $82.00 to $75.00. They now have an “outperform” rating on the stock.
  • 11/1/2019 – ANI Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 10/22/2019 – ANI Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/12/2019 – ANI Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/4/2019 – ANI Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “
  • 10/2/2019 – ANI Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.

Shares of ANIP stock traded up $0.33 on Thursday, reaching $57.39. The stock had a trading volume of 161,600 shares, compared to its average volume of 138,721. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.30. The firm’s 50-day moving average is $70.18 and its two-hundred day moving average is $72.84. The firm has a market capitalization of $673.90 million, a price-to-earnings ratio of 12.45 and a beta of 2.20. ANI Pharmaceuticals Inc has a 12 month low of $36.92 and a 12 month high of $86.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.43 by ($0.20). The firm had revenue of $51.30 million during the quarter, compared to the consensus estimate of $56.10 million. ANI Pharmaceuticals had a net margin of 7.58% and a return on equity of 28.28%. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.29 earnings per share. On average, sell-side analysts forecast that ANI Pharmaceuticals Inc will post 4.58 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Nuveen Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $7,071,000. Vanguard Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 564,317 shares of the specialty pharmaceutical company’s stock valued at $46,387,000 after purchasing an additional 12,859 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $211,000. THB Asset Management raised its holdings in shares of ANI Pharmaceuticals by 251.2% in the 2nd quarter. THB Asset Management now owns 89,305 shares of the specialty pharmaceutical company’s stock valued at $7,340,000 after purchasing an additional 63,874 shares during the period. Finally, Wedge Capital Management L L P NC grew its stake in ANI Pharmaceuticals by 8.6% in the 2nd quarter. Wedge Capital Management L L P NC now owns 7,386 shares of the specialty pharmaceutical company’s stock valued at $607,000 after buying an additional 586 shares during the last quarter. 72.28% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

See Also: What is an inverted yield curve?

Receive News & Ratings for ANI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.